Effects of Antidepressant Treatments on Platelet Tritiated Imipramine Binding in Major Depressive Disorder

Wagner, Annemarie; Åberg‐Wistedt, Anna; Åsberg, Marie; Bertilsson, Leif; Mårtensson, Björn; Montero, Dolores

doi:10.1001/archpsyc.1987.01800220032006

Cited by 40 publications

(12 citation statements)

References 81 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Previously no change in platelet 3 H-IMI binding amongst AD patients had been observed (Suranyi-Cadotte et al, 1985) although the possibility that associated depressive symptoms might have influenced this finding cannot be ruled out, since several studies (Raisman et al, 1981;Lewis et al, 1985;Waegner et al, 1987) have reported decreased platelet 3 H-IMI binding in patients affected by depressive illness.…”

Section: Discussionmentioning

confidence: 87%

Increased platelet 3H-imipramine binding and monoamine oxidase B activity in Alzheimer's disease

Bonuccelli

Piccini

Marazziti

et al. 1990

J Neural Transm Gen Sect

View full text Add to dashboard Cite

Several biochemical abnormalities in peripheral tissues have been reported in Alzheimer's disease (AD). With this in mind we studied platelet monoamine oxidase B (MAO B) activity and 3H-imipramine (IMI) binding in both AD patients and healthy subjects and found a significantly higher level of platelet MAO B activity and 3H-IMI Bmax values in the AD patients. In view of the part that MAO B plays in metabolizing serotonin (5HT) and of the relationship which exists between 3H-IMI binding and 5HT uptake, our results would suggest that with AD there occurs a complex dysfunction in the 5HT system, at least at a peripheral level.

show abstract

Section: Discussionmentioning

confidence: 87%

Increased platelet 3H-imipramine binding and monoamine oxidase B activity in Alzheimer's disease

Bonuccelli

Piccini

Marazziti

et al. 1990

J Neural Transm Gen Sect

View full text Add to dashboard Cite

show abstract

“…a sig nificant decrease in Bmax and an increase in IQ, as expected in view of in vitro data [29,30], This is in agree ment with a study of Wagner et al [31] who reported the same finding in 9 patients with major depression after 3 weeks of fluoxetine, as well as a slight increase in Bmax after 6 weeks. On the other hand, the data following treat ments with tricyclics are more controversial [32][33][34][35][36][37], Although 3H-IMI binding does not appear useful in assessing the severity of depressive symptoms, it is note worthy that it seems to identify, within depression, those subjects who respond better to treatment with a selective serotonergic drug such as fluoxetine. The patients in our sample who presented the lower HRSD score at ti, i.e.…”

Section: Discussionmentioning

confidence: 99%

Imipramine Binding as a Predictor of Fluoxetine Response in Depressed Patients

Castrogiovanni¹,

Muro²,

Marazziti³

1995

Neuropsychobiology

View full text Add to dashboard Cite

We evaluated platelet ³H-imipramine (³H-IMI) binding parameters (B_max and K_d) at baseline (t₀) and 2 months after (t₁) treatment with fluoxetine in a group of outpatients affected by a major depressive episode, according to DSM-IIIR criteria. The possible relationships between biological parameters and the Hamilton Rating Scale for Depression (HRSD) total score were examined. The results confirmed previous reports that depressed patients possessed a lower density (B_max) of platelet ³H-IMI binding sites than healthy controls, but the B_max tended to decrease with fluoxetine. In addition, we observed a negative correlation between B_max values at t₀ and the HRSD total scores at t₁ indicating that the patients who responded better to fluoxetine were those with a lower B_max at t₀. Future studies will substantiate this preliminary observation on the possible usefulness of platelet ³H-IMI binding as a predictor of pharmacological response.

show abstract

“…1987) have been reported. Non-pharmacological therapies, such as ECT and phototherapy, may also produce an increase in the lower than normal BmaX of pretreated depressed patients (Wagner et al, 1987;Maj et al, 1988;Szadoczky ef nl, 1989).…”

Section: Amdp-d B mentioning

confidence: 99%

Rapid changes in ₃H‐imipramine platelet binding after chronic treatment with amineptine, a selective dopamine uptake blocker, in major depressed patients

Gronier¹,

Jeanningros²

1992

Fundamemntal Clinical Pharma

View full text Add to dashboard Cite

The effect of chronic treatment with amineptine (200 mg daily), a tricyclic antidepressant drug selectively blocking dopamine uptake, on 3H-imipramine binding, was investigated in platelets of major depressed patients in conjunction with changes in clinical state. Before treatment, depressed patients had a significantly lower Bmax (P less than 0.01) than age- and gender-matched healthy controls. After only 1 week of amineptine administration, Bmax values increased significantly (P less than 0.01) and reached the control value concomitantly with a large and significant clinical improvement (P less than 0.01). After 1 month, Bmax was still significantly different from the pretreatment value (P less than 0.05), and not significantly different from the control value, while the improvement in clinical status persisted. No significant changes in Kd values were observed during treatment. We also verified that amineptine did not displace 3H-imipramine binding from platelets either in depressed or in control subjects. The results show that the successful treatment with amineptine, an antidepressant drug devoid of affinity for the tritiated imipramine platelet binding site, can rapidly lead to its density normalization.

show abstract

Effects of Antidepressant Treatments on Platelet Tritiated Imipramine Binding in Major Depressive Disorder

Cited by 40 publications

References 81 publications

Increased platelet 3H-imipramine binding and monoamine oxidase B activity in Alzheimer's disease

Increased platelet 3H-imipramine binding and monoamine oxidase B activity in Alzheimer's disease

Imipramine Binding as a Predictor of Fluoxetine Response in Depressed Patients

Rapid changes in ₃H‐imipramine platelet binding after chronic treatment with amineptine, a selective dopamine uptake blocker, in major depressed patients

Contact Info

Product

Resources

About

Effects of Antidepressant Treatments on Platelet Tritiated Imipramine Binding in Major Depressive Disorder

Cited by 40 publications

References 81 publications

Increased platelet 3H-imipramine binding and monoamine oxidase B activity in Alzheimer's disease

Increased platelet 3H-imipramine binding and monoamine oxidase B activity in Alzheimer's disease

Imipramine Binding as a Predictor of Fluoxetine Response in Depressed Patients

Rapid changes in 3H‐imipramine platelet binding after chronic treatment with amineptine, a selective dopamine uptake blocker, in major depressed patients

Contact Info

Product

Resources

About

Rapid changes in ₃H‐imipramine platelet binding after chronic treatment with amineptine, a selective dopamine uptake blocker, in major depressed patients